3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
189
Neoplasm Metastasis
19
Neoplasms
9
Ovarian Neoplasms
8
Breast Diseases
6
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Advanced Breast Cancer
4
Neoplasms by Site
3
Lung Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Neoplasm, Residual
2
Multiple Myeloma
2
Melanoma
2
Inflammation
2
Hematologic Neoplasms
2
Fallopian Tube Neoplasms
2
Estrogen Receptor-positive Breast Cancer
2
Interventions
abemaciclib
2
Radiotherapy
2
sargramostim
1
ribociclib
1
palbociclib
1
niraparib
1
exemestane
1
Mastectomy, Segmental
1
Mastectomy
1
Letrozole
1
Growth and Development
1
Fulvestrant
1
Everolimus
1
Cyclophosphamide
1
Continuous Positive Airway Pressure
1
Colony-Stimulating Factors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unilateral Breast Neoplasms
×
palbociclib
×
Breast
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled